B-Ingelheim NASH Deal Boosts Pharmaxis’s Revitalization
This article was originally published in PharmAsia News
The eagle has landed for Australian drug discoverer Pharmaxis in the form of a major deal with Boehringer Ingelheim for a non-alcoholic steatohepatitis (NASH) treatment, and the Sydney-based firm says it is ready to soar again following the transaction.
You may also be interested in...
Scrip begins its week at the BIO International Convention with interviews and panel discussions about dealmaking and progressing development pipelines. Among the first day highlights: Janssen's hunt for technology, Boehringer's NASH plans and rising investment in neuroscience.
Cynata has inched closer to a major global partnership after signing a term sheet with Fujifilm for cell therapy technologies that has been described by analysts as a potentially transformative deal.
As a former war correspondent on the battlefields of the Balkans, Afghanistan and Iraq, new Avita Medical chief executive Adam Kelliher can claim to have an up-close understanding of the types of injuries that his regenerative medicine company’s lead product is designed to heal.